Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

NCT00467012 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT00467012
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00467012 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2007
Completion date
September 30, 2011
Enrollment
122 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer